Arabian Levantine viper bite induces thrombocytopenia – a case report

Ayman Abukamar1*, Rawan Abudalo2, Mazen Odat3, Mohammad Al-Sarayreh1, Maher Bani Issa1, Asem Momanie1

Author Affiliations
1. Department of Hematology and Oncology, King Hussein Medical City, Amman, Jordan
2. Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa, Jordan
3. Department of Neurology Unit, King Hussein Medical City, Amman, Jordan

*Corresponding Author:
Ayman Abukamar,
Department of Hematology and Oncology,
King Hussein Medical City,
Amman, Jordan.
E-mail: aymanjor2020@hotmail.com

ABSTRACT
Snakebites have been reported to induce hematological complications. Thrombocytopenia usually occurs secondary to disseminated intravascular coagulation (DIC) and coagulopathy induced by the snake bite. However, thrombocytopenia can develop after the snake bite, even in the absence of significant coagulopathy. We reported the case of a 36-year-old Jordanian male patient who was bitten by Arabian Macrovipera Lebetina Obtusa (Levantine viper), which developed venom-induced severe thrombocytopenia without coagulopathy. A progressive drop in platelet count was observed during his admission. His condition improved after anti-venom therapy, and he was discharged after 4 weeks of treatment for a full recovery. This case supports that snake venom can produce severe thrombocytopenia without significant coagulopathy, which can be treated successfully with anti-venom and the best supportive care.

KEYWORDS: thrombocytopenia, disseminated intravascular complications (DIC), snake bite.

INTRODUCTION
Currently, about 3000 snake species are known worldwide. However, only 15% of these are venomous and, thus, dangerous to humans [1]. Males between 17 and 27 years are the most susceptible to snake bites with upper limbs as the usual site. Snake bites must always be taken seriously and immediate medical attention is obligatory because these may induce death if not treated quickly and adequately [1–3].

Extreme age, improper handling of captive snakes (rather than wild encounters), delay in treatment, and insufficient treatment are risk factors that can cause death [4]. According to the World Health Organization (WHO), about 4.5 to 5.4 million snake bites occur each year worldwide, and 1.8 to 2.7 million of these cases develop illnesses [2]. It is estimated that at least 81,000 to 138,000 people die from snake bites each year [2].

The venom of a snake is complex, and it contains various toxins that are known to attack different organs in the body. While different species carry different types of venom, the major effects of venoms include the following [5]:

1. Cytotoxins lead to swelling and necrosis of the affected part.
2. Hemorrhage induces disseminated intravascular coagulation (DIC), low platelets, and disrupts the blood vessels.
3. Neurotoxins lead to flaccid paralysis of the victim.
4. Myotoxins break down muscles, which leads to renal failure and electrolyte imbalance, and may, in turn, lead to cardiac arrest.

Macrovipera lebetina is a medically important species of snake. Subspecies from the Levantine viper are capable of causing hematological manifestations and necrosis, as seen in the case reported here. This snake is found in North Africa, the Middle East, and the Far East and is defined by the WHO grading scale as a class II snake of medical significance [6–8].

Five subspecies are currently recognized for Macrovipera lebetina (ML), mentioned in Table 1 [9, 10].

Levantine viper (Macrovipera lebetina obtusa) is a large snake with a length that possibly exceeds 150 cm and a triangular head that is clearly distinct from the neck (Figure 1 A, B). Interestingly, there is a difference in size between the sexes as females are larger than males.

Belonging to the family of Viperidae, Levantine has a very limited distribution in the Rocky Mountains with low vegetation in Tafilah Governorate in southern Jordan [11].

The bite of Macrovipera lebetina obtusa can cause death. However, the mortality rate is unknown, as there are poor accurate statistics due to insufficient documented data from the countries where this snake is found. In addition to the local effects,
i.e., pain, progressive edema, ecchymosis, and blisters, other systemic effects can occur, including nausea, vomiting, dyspnea, neurologic abnormalities, hypotension, shock, and hematological abnormalities. Viperidae envenomation is mostly known to cause coagulopathy disturbances, including mucosal and internal hemorrhages, thrombocytopenia, and a decrease in coagulation factors [12–14].

The venoms produced by the deadly Viperidae snake family contain hemotoxin and vasculotoxic components [13–15]. Hence, following their envenomation, coagulopathy disturbances, including spontaneous bleeding and thrombocytopenia, are predictable complications [16, 17]. Several hematological consequences can occur after a snake bite, including platelet aggregation and adenosine triphosphate (ATP) release by platelet aggregating proteins, platelet inactivation due to binding of venom antigens to platelet integrins, consumption of coagulation factors, and damage to blood vessels. Anti-venom administration can restore coagulopathy sufficiently and rapidly [16]. However, thrombocytopenia seems difficult to resolve, and the victim has 3.1 times the risk of difficulty in achieving the normal range of platelets [18].

Most patients who have been bitten by snakes received anti-venom administration during their admission to the hospitals. The main goal of the anti-venom administration is to obtain neutralization of the venom inside the body, thereby disabling its action and effects.

### CASE REPORT

A 36-year-old male, who works as a farmer, presented to the emergency room at his local hospital after being bitten by a snake on the dorsum of the left foot while he was watering the field. He complained of pain in the left leg and dizziness associated with the swelling at the site of the snake bite. The pain was diffuse, burning in nature. It was ascertained through clinical examination that his vital signs were stable, and his left foot and ankle joint was swollen and hot. Later, a black discoloration developed at the site of the bite (Figure 2) with ecchymosis. A lab test immediately revealed the following: White blood cells (WBCs) count was 7.5×10^3/μL, 68% neutrophils, hemoglobin was 11.5 g/dl, platelets count was 114×10^3/μL, and the international normalized ratio (INR) was 1.1 with normal prothrombin time (PT), partial thromboplastin time (PTT), and kidney function test (KFT).

After hospitalization, supportive treatment with IV fluids and IV antibiotics was started immediately in addition to anti-venom administration. In the lab investigations repeated 6 hours later, the INR remained normal, his hemoglobin was 10.1 g/dl, and the platelets count was 103×10^3/μL. However, with subsequent days, his platelet count dropped more and more without significant coagulopathy with a progressive increase in the swelling of the left leg. He was referred to the King Hussein Medical City (KHMC), a tertiary hospital in Amman/Jordan.

Upon arrival, his vital signs were stable, he was fully conscious, and there was no neurological deficiency. However, his left leg was swollen with ecchymosis, and diffuse subcutaneous bleeding was reported on examination (Figure 3). Further laboratory tests were repeated, which revealed the following: hemoglobin level was 9.8 g/dl, platelets count was 99.7×10^3/μL, INR was 1.24, WBCs count was 7.57×10^3/μL, and normal KFT. After hospitalization in our hospital, he received the best supportive care, but a progressive drop in the platelet count was observed each subsequent day until it reached 2×10^3/μL. Blood film and manual platelet count revealed neutrophilic leukocytosis and normochromic normocytic anemia, and the manual count for the aggregated platelets with thrombocytopenia was 50000×10^3/μL. The patient received the best supportive care until full recovery and was discharged from the hospital after 5 weeks with adequate

---

**Table 1. Subspecies of Macrovipera lebetina in the world.**

| Subspecies                        | Locations                                                                 |
|-----------------------------------|---------------------------------------------------------------------------|
| Macrovipera lebetina obtusa       | Jordan, Syria, Lebanon, Iraq, Turkey, India, Pakistan (Kashmir), Caucasus, Azerbaijan, Dagestan, Iran and southern Afghanistan |
| Macrovipera lebetina lebetina     | Cyprus                                                                    |
| Macrovipera lebetina cernovi      | Southern Turkmenistan, Pakistan (Kashmir) northern Afghanistan and Iran    |
| Macrovipera lebetina transm Nationwide | Uzbekistan, Tajikistan, Eastern Turkmenistan, southwestern Kazakhstan, parts of western Pakistan and northern Afghanistan |

---

**Figure 1. Arabian Macrovipera Lebetina Obtusa (Levantine viper). A – Live snake photo has been taken by the Royal Society for the Protection of Nature/Jordan. B – The snake killed by the patient.**
Figure 2. Patient’s left foot after the snake bite. Swelling associated with discoloration was reported.

Figure 3. Representative image of patient’s left leg with diffuse subcutaneous hemorrhage, which involved the whole limb.
The severity of these consequences depends on the amount of venom and site of the bite. The hematological consequences of a snake bite are several, including DIC, hemolysis, thrombocytopenia, and bleeding due to consumption of clotting factors. Both development of DIC and an increase in vascular permeability may be observed. Bleeding ranged from subcutaneous to severe such as hematuria and hemoptysis. Indeed, thrombocytopenia can occur after a snake bite without significant coagulopathy, as discussed in our case. As such, the proposed mechanisms of thrombocytopenia are related to the increase of platelet aggregations induced by the venom or anti-venom or due to direct destruction of the platelets since another mechanism may coexist. Platelet transfusion is eventually required if severe thrombocytopenia or bleeding to major organs has occurred.

Thrombocytopenia usually improved with anti-venom administration and supportive treatment for most patients, but sometimes, prolonged periods were required for complete recovery.

CONCLUSION

The reported case supports the hypothesis that thrombocytopenia can occur without coagulopathy after a snake bite.

ACKNOWLEDGMENTS

Conflict of interest
The authors declare no conflict of interest.

Consent to participate
An informed consent form has been obtained from the patient to publish this case report and any accompanying images and clinical or personal details.

Authorship
AA and RA contributed to the manuscript writing. MA-S, and MBI created the table and the figures. AM contributed to manuscript editing. All authors read and approved the final manuscript.

REFERENCES

1. Gold BS, Barish RA, Dart RC. North American snake envenomation: diagnosis, treatment, and management. Emerg Med Clin North Am. 2004 May;22(2):423-43, ix. doi: 10.1016/j.emc.2004.01.007.
2. Alcolia G, Chabloz M, Eyong J, Wanda F, et al. Snakebite epidemiology and health-seeking behavior in Akonolinga health district, Cameroon: Cross-sectional study. PLoS Negl Trop Dis. 2020 Jun 25;14(6):e0008334. doi: 10.1371/journal.pntd.0008334.
3. Gold BS, Dart RC, Barish RA. Bites of venomous snakes. N Engl J Med. 2002 Aug 1;347(5):347-56. doi: 10.1056/NEJMoa0203477.
4. Adakakunte D, Varanauskas E, Adakakunte A. Venomous snakebites. Medicine (Kaunas). 2011; 47:461-467.
5. Ahmed S, Ahmed M, Nadeem A, Mahajan J, et al. Emergency treatment of a snake bite: Pearl from literature. Journal of Emergencies, Trauma, and Shock. 2008;1:97-105. doi:10.1016/j.jets.2007.10.001.
6. Nalbantosy A, Karabay-Yaracoglu N, Sayan F, Delihoglu-Gurhan Gocmen B, et al. Determination of in vivo toxicity and in vitro cytotoxicity of venom from the Cypriot blunt-nosed viper Macrocestus lebetina lebetina and anti-venom production. Journal of Venomous Animals and Toxins including Tropical Diseases. 2012;18:208-216.
7. Jestrzenski D, Kuzaykova I. Morphometric characteristics and seasonal proximity to water of the Cypriot blunt-nosed viper Macrocestus lebetina lebetina (Linnaeus, 1758). Journal of Venomous Animals and Toxins including Tropical Diseases. 2018;24:42. https://doi.org/10.13948/j.40093.013-0175-6
8. Sharma R, Lal V, Simpson I. Snakes of Medical Significance in India: The First Reported Case of Envenoming by the Levantine Viper (Macrovipera lebetina). Wilderness & Environmental Medicine. 2008;19:195-198. https://doi.org/10.1580/07-WEME-CR-175.1.
9. Siigur J, Aspöllu A, Stigur E. Biochemistry and pharmacology of proteins and peptides purified from the venoms of the snakes Macrocestus lebetina subspecies. Toxicicon. 2019; 158:16-32. doi:10.1016/j.toxicon.2018.11.29410.
10. Monadi N, Rastegar-Pooyani N, Rastegar-Pooyani E. Geographic variation in the morphology of Macrocestus lebetina Linnaeus, 1758: (Ophidia: Viperidae) in Iran. Acta Herpetologica. 2014; 9:107-202. doi:10.13128/Acta_Herpetol-14384.
11. Amu Z, Dusi A. Systematics, distribution and ecology of the snakes of Jordan. The Journal of Basic and Applied Zoology. 2011; 61:179-266.
12. Mosunzi SM, Dadasюр B, Ahhari R. Snakebite management in Iran: Devising a protocol. J Res Med Sci. 2014 Feb;19(2):153-63.
13. Warrell DA. Venomous bites, stings, and poisoning. Infectious Disease Clinics of North America. 2002; 16:207-225. DOI:10.1016/j.idc.2012.03.006.
14. Gold BS, Dart RC, Barish RA. Bites of venomous snakes. N Engl J Med. 2002 Aug 1;347(5):347-56. doi: 10.1056/NEJMoa0203477.
15. Shinmamnarayana J, Dutta TK, Sahai A, Bahinathan S. Rational use of anti-snake venom (ASV): trial of various regiments in hemotoxic snake envenomation, J Assoc Physicians India. 2004 Oct;52:788-91.
16. Ishbiter GK. Snakebite doesn’t cause disseminated intravascular coagulation: coagulopathy and thrombotic microangiopathy in snake envenoming. Semin Thromb Hemost. 2010 Jan;36(1):44-51. doi:10.1055/s-0030-1254053.
17. Kleiman SS, Friedman JE, Tracy PR, Furie BC, et al. Platelet developmental biology, physiology, and translatable platforms for preclinical investigation and drug development. Platelets. 2008 Jan;19(1):29-31. doi: 10.1080/09537100701491742.
18. Yin S, Koko J, Lavona E, Milychak S, et al. Factors associated with difficulty achieving initial control with crotidae polyvalent immune fab anti-venom in snakebite patients. Acad Emerg Med. 2011 Jan;18(1):46-52. doi:10.1111/j.1553-2712.2010.00950.x.

Table 2. Patient’s laboratory results after the snake bite.

| Test     | D1  | D2  | D3  | D4  | D5  | D10 | D15 | D20 | D25 | D30 |
|----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| WBCs     | 7.5 | 8.1 | 7.57| 20.0| 13.34| 12.75| 17.49| 12.02| 10.6 | 10.3 |
| Hb       | 11.5| 10.1| 9.8 | 11.3| 10.9 | 10.8 | 11   | 11.8 | 13.4 | 12.2 |
| Platelets| 114 | 103 | 99.7| 41  | 6   | 2   | 9   | 6   | 14.1 | 145  |
| INR      | 1.13| 1.29| 1.24| 1.06| 1.14 | 1.12 | 0.97 | 1.02 | 1.1  | 0.97 |
| PT       | 12.2| 17.2| 16.5| 14.2| 15.2 | 15   | 13.2 | 13.8 | 14.5 | 14.1 |
| PTT      | 21.6| 27.6| 25.8| 24.8| 25   | 25.1 | 24.8 | 25   | 27.1 | 26.3 |
| Creatinine| 0.6 | 0.9 | 0.85| 0.9 | 1.0  | 1.1  | 0.9  | 0.8  | 1.0  | 0.9  |

Lab tests were done at different points in time; day 1 (D1), day 2 (D2), day 5 (D5), day 6 (D6), day 7 (D7), day 10 (D10), Day 15 (D15), day 20 (D20), day 25 (D25), and day 30 (D30).